MBX Biosciences, Inc. Common Stock (MBX) Price/OCF Ratio: History & Chart

MBX Biosciences, Inc. Common Stock(MBX)

Biotechnology · Carmel, IN

$56.83-1.71 (-2.92%)

Delayed quote: Oct 6, 2026, 11:05 AM EDT

About MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Carmel, IN

63 employees

mbxbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Steve Hoerter

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
MBX Biosciences, Inc. Common Stock (MBX)	$2.70B	N/A	N/A	N/A	N/A
Acadia Healthcare Company, Inc. (ACHC)vs ›	$2.71B	12.85	10.38	21.92	19.88
Aveanna Healthcare Holdings Inc. (AVAH)vs ›	$2.69B	16.01	17.24	48.15	48.31
Neogen Corporation (NEOG)vs ›	$2.69B	32.32	27.18	41.42	45.39
Beam Therapeutics Inc. (BEAM)vs ›	$2.64B	N/A	39.43	39.43	39.43
AtriCure, Inc. (ATRC)vs ›	$2.77B	42.69	33.50	475.62	475.62
NewAmsterdam Pharma Company N.V. (NAMS)vs ›	$2.61B	N/A	8.27	8.27	8.27
TransMedics Group, Inc. (TMDX)vs ›	$2.81B	19.23	24.35	65.42	65.42
Dyne Therapeutics, Inc. (DYN)vs ›	$2.88B	N/A	N/A	N/A	N/A
Disc Medicine, Inc. (IRON)vs ›	$2.45B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

MBX Biosciences, Inc. Common Stock (MBX)

$2.70B

N/A

Acadia Healthcare Company, Inc. (ACHC)vs ›

$2.71B

12.85

10.38

21.92

19.88

Aveanna Healthcare Holdings Inc. (AVAH)vs ›

$2.69B

16.01

17.24

48.15

48.31

Neogen Corporation (NEOG)vs ›

$2.69B

32.32

27.18

41.42

45.39

Beam Therapeutics Inc. (BEAM)vs ›

$2.64B

N/A

39.43

AtriCure, Inc. (ATRC)vs ›

$2.77B

42.69

33.50

475.62

NewAmsterdam Pharma Company N.V. (NAMS)vs ›

$2.61B

N/A

8.27

TransMedics Group, Inc. (TMDX)vs ›

$2.81B

19.23

24.35

65.42

Dyne Therapeutics, Inc. (DYN)vs ›

$2.88B

N/A

Disc Medicine, Inc. (IRON)vs ›

$2.45B

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

MBX Price/OCF Ratio Metrics

MBX Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics